Polynucleotides encoding anti-GD2 antibodies
AssigneeMorphotek, Inc.
InventorsNicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
Life of this patent
Estimating the term…
Loading patent…
AssigneeMorphotek, Inc.
InventorsNicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
Estimating the term…
Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.
An isolated polynucleotide encoding an antibody, or antigen binding fragment thereof, that specifically binds to human GD2, having a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
A recombinant polynucleotide encoding an antibody heavy chain, or a fragment thereof, of an antibody that specifically binds to human GD2, wherein the heavy chain CDR1 of the antibody comprises the amino acid sequence of SEQ ID NO:
An isolated cell comprising a vector having a recombinant polynucleotide encoding an antibody heavy chain, or a fragment thereof, of an antibody that specifically binds to human GD2, wherein the encoded heavy chain or fragment thereof includes a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:12, the isolated cell further comprising a separate vector having a recombinant polynucleotide encoding an antibody light chain, or a fragment thereof, of an antibody that specifically binds to human GD2, wherein the encoded light chain or fragment thereof includes a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:26, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:28.
Dependencies are inferred from the claim text.